February, 2023

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Cardiovascular Complications from COVID-19 mRNA Vaccines

Director | 24/02/2023 | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Yasmin, F., Najeeb, H., Naeem, U., Moeed, A., Atif, A. R., Asghar, M. S., Nimri, N., Saleem, M., Bandyopadhyay, D., Krittanawong, C., Eljack, M. M. F., Tahir, M. J., & Waqar, F. (2023). Adverse events following COVID‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immunity, Inflammation and Disease, 11, e807. […]

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Reference Library, Statistical evidence, Vaccines, Viral illnesses

Restricted content

Suzanne | 23/02/2023 | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Reference Library, Statistical evidence, Vaccines, Viral illnesses

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Effectiveness of the COVID-19 Bivalent Vaccine

Director | 23/02/2023 | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Shrestha, N. K., Burke, P. C., Nowacki, A. S., Simon, J. F., Hagen, A., & Gordon, S. M. (2022). Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine. medRxiv. https://doi.org/10.1101/2022.12.17.22283625 Summary: This study evaluated the effectiveness of the bivalent COVID-19 vaccine among 51,011 employees at the Cleveland Clinic. The results indicated a 30% effectiveness

COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine safety & adverse events, Vaccines, Viral illnesses

Restricted content

Suzanne | 16/02/2023 | COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine safety & adverse events, Vaccines, Viral illnesses

COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine safety & adverse events, Vaccines, Viral illnesses

Restricted content

Suzanne | 09/02/2023 | COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine safety & adverse events, Vaccines, Viral illnesses

COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Restricted content

Suzanne | 02/02/2023 | COVID-19, Covid-19 vaccines, Ethics, Reference Library, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Comprehensive Prevention Strategies Against COVID-19, Influenza, and RSV – SUMMARY

Director | 02/02/2023 | COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Reference: FLCCC Alliance. (2023). I-PREVENT COVID, FLU AND RSV protection. Retrieved from www.flccc.net Summary: The I-PREVENT protocol is designed for healthcare workers, high-risk individuals, and those with co-morbidities to mitigate the risks of COVID-19, influenza, and RSV infections. Recommended interventions include antiseptic mouthwashes containing chlorhexidine, povidone-iodine, or cetylpyridinium chloride, and supplementation with Vitamin D, Vitamin

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Other viral illnesses, Resource Type, Treatment, Viral illnesses

Preventative Protocols for COVID-19, Influenza, and RSV

Director | 01/02/2023 | COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Other viral illnesses, Resource Type, Treatment, Viral illnesses

Reference: I-PREVENT. (2023). COVID, Flu and RSV protection. Retrieved from [source link if applicable, otherwise remove this line] Summary: The I-PREVENT protocol offers strategies for the prevention of COVID-19, influenza, and RSV. It includes pre-exposure and post-exposure prevention measures, particularly aimed at high-risk groups and healthcare workers. The pre-exposure approach recommends the use of antiseptic

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Association of Guillain-Barré Syndrome with COVID-19 Vaccination

Director | 01/02/2023 | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Abara, W. E., Gee, J., Marquez, P., Woo, J., Myers, T. R., DeSantis, A., Baumblatt, J. A. G., Woo, E. J., Thompson, D., Nair, N., Su, J. R., Shimabukuro, T. T., & Shay, D. K. (2023). Reports of Guillain-Barré syndrome after COVID-19 vaccination in the United States. JAMA Network Open, 6(2), e2253845. https://doi.org/10.1001/jamanetworkopen.2022.53845 Summary:

February 2023